author-photo

Laurence Legros

French Institute of Health and Medical Research

209

Papers

6037

Citations

Citation Trend

Filter By

Papers (149) Sort By

Journal Conference Others

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Recherche d’anticorps anti-érythrocytaires en présence de médicament : premier cas de réaction croisée avec deux produits de contraste iodés

2021 Transfusion Clinique Et Biologique
Show All
- Source
- Cite
- Save
Citations (0)
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (3)
Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.

2020 Journal of Thrombosis and Thrombolysis
Show All
- Source
- Cite
- Save
Citations (2)
The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

2019 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

2019 Blood
Show All
- Source
- Cite
- Save
Citations (12)
Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (43)
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

2019 Haematologica
Show All
- Source
- Cite
- Save
Citations (26)